Atea Pharmaceuticals, Inc. — Director's Dealing 2021

Feb 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2021-01-29

Reporting Person: Sommadossi Jean-Pierre (Director, President, CEO, and Chairman)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-29	Stock Option (Right to Buy)	$73.00	A	640000	Acquired	2031-01-28	Common Stock (640000)	Direct

Footnotes

F1: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 29, 2021.